Table 1. Recorded dispensing and pill returns by study visit and trial arm.
| Number of tablets (doses) | Trial arm | Enrolment | 2w visit | 12w visit | 24w visit | 36 w visit | Overall |
|---|---|---|---|---|---|---|---|
| Dispensed | Placebo | 3038 (806) | 7420 (1947) | 8528 (2221) | 8315 (2151) | 8219 (2092) | 35,520 (9216) |
| AZM | 2767 (790) | 7059 (2014) | 8070 (2289) | 7946 (2189) | 7728 (2121) | 33,570 (9403) | |
| Presumed to be consumed | Placebo | 1732 (462) | 5822 (1521) | 6687 (1742) | 6909 (1783) | 6697 (1689) | 27,847 (7197) |
| AZM | 1639 (466) | 5444 (1563) | 6475 (1869) | 6443 (1770) | 6401 (1756) | 26,402 (7424) | |
| Returned | Placebo | 1173 (310) | 1389 (364) | 1385 (367) | 1185 (301) | 1132 (298) | 6,264 (1661) |
| AZM | 1152 (325) | 1343 (379) | 1178 (324) | 1323 (359) | 1216 (335) | 6212 (1722) | |
| Not accounted for | Placebo | 133 (34) | 209 (62) | 456 (112) | 221 (67) | 390 (105) | 1409 (379) |
| AZM | 0 (0) | 248 (71) | 417 (95) | 180 (60) | 111 (30) | 932 (255) | |
| Number of visits with apparent over-adherence (>115%) | Placebo | - | 18 (10.3%) | 10 (5.8%) | 12 (6.9%) | 12 (6.9%) | 52 (7.5%) |
| AZM | - | 15 (8.7%) | 2 (1.2%) | 7 (4.1%) | 9 (5.2%) | 33 (4.8%) |
Apparent over-adherence is where the participant did not return the buffer doses, and was presumed to consume more than 15 doses in the first 12 weeks, or more than 14 doses in subsequent periods.